All News

Hip

Pfizer/Lilly Pull Tanezumab Development

d Jack Cush, MD

Today, Lilly and Pfizer announced their global clinical development of the NGF inhibitor, tanezumab, has been discontinued due to recent negative opinions from the EMA and FDA advisory committee.

Read Article
liver,hepaitis,pink,gb

New Hope for NonAlcoholic Fatty Liver Disease

d Jack Cush, MD

The current issue of the NEJM has two articles on nonalcoholic fatty liver disease (NAFLD also called NASH - nonalcoholic steatohepatitis), one dealing with the prognoses, outcomes and mortality of NAFLD and another prospective and promising interventional trial in NASH patients. 

Read Article
syringe,needle,vaccine

How Should Patients With Autoimmune Diseases Approach COVID Vaccination?

d MedPage Today

Healthcare is a personal and individualized relationship between a provider and patient. Each patient is treated according to their particular symptoms and personal health characteristics.

Read Article
Register now to receive #ACR21 news and select topic emails throughout the conference. https://t.co/riyAnrRHhX https://t.co/ufGxXnbtoG

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatic pts admitted to ICU, #SLE is most common & Sepsis most common reason. 80 ARD pts adm to ICU: Dx were SLE (42%), RA (26%), vasculitis (12%) FOR Sepsis (31%), (10%) CHF (10%). 20% died in ICU, 5% 30d after ICU, 7.5% w/in 1 yr https://t.co/lX0m3vOukI

Links:

Dr. John Cush RheumNow ( View Tweet)

Short (3 min) walks intstead of sitting benefits RA w/ anticytokine effect (TNF, IL1RA), improved glucose, c-peptide, insulin. Crossover study 15 RA women who had 1) prolonged sitting, 2) 30-min mod-vigor exercise or 3) 3-min of light walking every 30 min https://t.co/36AnhHL9OI

Links:

Dr. John Cush RheumNow ( View Tweet)

New Download Available! FDA EUA for Baricitinib in COVID https://t.co/yTQLb7DDvR https://t.co/n9Npg0Pq5q

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: QD Clinic - Severe Arthritis Numbers QD Videos are brought to you by RheumNow's upcoming coverage of ACR 2021 https://t.co/QgBL4dnCk7

Links:

Dr. John Cush RheumNow ( View Tweet)

From March to Dec 2020, study of 116K COVID pts saw monthly rates of hospitalization (105/100K), ICU admits (20/100K), & death (12/100K) -peaked 12/20. Highest w/ age >65yrs, hispanics, blacks. Remdesivir incr 1.7% to 54%; Steroids 19% to 74.2% https://t.co/5pzu74YIz6

Links:

Dr. John Cush RheumNow ( View Tweet)

83 patients w/ ANCA Assoc. Vasculitis, hospital admited, 44 died in-ICU (53%) w/ death by infection (61%), active vasculitis (34%). Predictors of ICU death were APACHE II score (OR=1.3) and respiratory failure (OR=620). https://t.co/ZPBkVWy40I

Links:

Dr. John Cush RheumNow ( View Tweet)

Among 825,556 sepsis pts in Taiwan (2003–2017), having SLE increased mortality risk 3 fold (HR 2.8;2.5–3.2), w/ adjustments (HR 1.47). Other risk factors: age (1.02), prednisolone > 5mg/d (1.55), MTX (2.19) & immunosuppressives (1.45) https://t.co/d1OPrjgshz

Links:

Dr. John Cush RheumNow ( View Tweet)

Israeli study of 1497 fully vaccinated health care workers finds 39 (2.4% Breakthrough COVID infections (Jan-May 2021), most cases were mild or asymptomatic, 19% w/ persistent Sxs (>6 ws); infected had lower neutralizing Abs. https://t.co/deYTVLRQCU

Links:

Dr. John Cush RheumNow ( View Tweet)

ATOM study - Phase 3 RCT testing abaloparatide (Tymlos) in 228 men with osteoporosis. At 12 mos Tymlos shows signif increase in lumbar BMD of 1.2%. Also increased were hip and femoral neck BMD at 12 months. https://t.co/WC3ygkyMZH

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: In a real world study of lupus patients, aspirin use lowered risk of preeclampsia, as did hydroxychloroquine. Risk Factors for preeclampsia were high Dz activity 1st trimester(OR 4.55),BMI >30 (6.14),antiphospholipid synd (8.02),hx preeclampsia (9.8)https://t.co/giBamMAPRM https://t.co/NHKxlmEHQj

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatologist Smoke-Enders available for download wherever you get your podcasts. https://t.co/o35tuNgk8R https://t.co/pksojrC5Wb

Links:

Dr. John Cush RheumNow ( View Tweet)
"Progress is a nice word. But change is its motivator and change has its enemies." - Robert F. Kennedy https://t.co/sIVym3e80c
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Nice full read review of IL-23 in Rheumatology - its biology and clinical targeting. IL-23 is a coordinating cytokine in psoriasis, psoriatic arthritis and inflammatory bowel disease. https://t.co/tDWZuV6Tao https://t.co/0p8RGnnE9B

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Propensity matched comparison of Tramadol vs Codeine use. Tramadol had a signif. higher risk of all-cause mortality (HR, 2.31), CV events (HR 1.15) & fractures (HR 1.50), but no diff in falls, delirium, constipation, opioid abuse, sleep disorders. https://t.co/nBUe5VV1D3 https://t.co/C3r0Fur4xJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Congratulations to friend and mentor, Dr. Stan Cohen for receiving this years ACR Gold Medal award - the highest award that the ACR can bestow. Stan was a past ACR President & has been a leading educator and researcher in rheumatology https://t.co/EJQ5tc3dhc

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI:Pregabalin (lyrica) for Fibromyalgia 75 mg bid; may be increased to max dose 450 mg/d.(Reduce for renal dz). Indications: DM neuropathy/pain, post-herpetic neuralgia, partial seizures. Rare AE: Angioedema, low Plts, ^PR interval, rhabdo, gynecomastia https://t.co/r4cH7n9qWD

Links:

Dr. John Cush RheumNow ( View Tweet)

×